Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 65

1.

Real-World Evidence Data on Metastatic Renal-Cell Carcinoma Treatment in Austria: The RELACS Study.

Schmidinger M, Pichler R, Loidl W, Bauernhofer T, Kretz M, Tinchon C, Niedersüß-Beke D, Pfleger G, Wiesinger CG, Vogl U, Mitterberger M, Stöger H, Tulchiner G, Kratochvill F, Gerritsmann H, Mraz B, Marszalek M.

Clin Genitourin Cancer. 2019 May 25. pii: S1558-7673(19)30155-7. doi: 10.1016/j.clgc.2019.05.017. [Epub ahead of print]

PMID:
31235275
2.

Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope?

Pichler R, Compérat E, Klatte T, Pichler M, Loidl W, Lusuardi L, Schmidinger M.

Cancers (Basel). 2019 Mar 25;11(3). pii: E422. doi: 10.3390/cancers11030422.

3.

Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.

Dieckmann KP, Radtke A, Geczi L, Matthies C, Anheuser P, Eckardt U, Sommer J, Zengerling F, Trenti E, Pichler R, Belz H, Zastrow S, Winter A, Melchior S, Hammel J, Kranz J, Bolten M, Krege S, Haben B, Loidl W, Ruf CG, Heinzelbecker J, Heidenreich A, Cremers JF, Oing C, Hermanns T, Fankhauser CD, Gillessen S, Reichegger H, Cathomas R, Pichler M, Hentrich M, Eredics K, Lorch A, Wülfing C, Peine S, Wosniok W, Bokemeyer C, Belge G.

J Clin Oncol. 2019 Jun 1;37(16):1412-1423. doi: 10.1200/JCO.18.01480. Epub 2019 Mar 15.

PMID:
30875280
4.

High economic burden of immunotherapy underlines the need of predictive biomarkers for the individual therapy algorithm in metastatic bladder cancer.

Pichler R, Loidl W, Pichler M.

Transl Androl Urol. 2018 Dec;7(Suppl 6):S738-S740. doi: 10.21037/tau.2018.08.15. No abstract available.

5.

[Immunotherapy].

Grimm MO, Loidl W.

Urologe A. 2018 Nov;57(11):1299-1300. doi: 10.1007/s00120-018-0796-y. German. No abstract available.

PMID:
30406452
6.

[Immunotherapy for locally advanced and metastasized bladder cancer].

Loidl W, Luger F.

Urologe A. 2018 Nov;57(11):1334-1341. doi: 10.1007/s00120-018-0785-1. Review. German.

PMID:
30302494
7.

Prognostic Value of Testing PD-L1 Expression After Radical Cystectomy in High-risk Patients.

Pichler R, Fritz J, Lackner F, Sprung S, Brunner A, Horninger W, Loidl W, Pircher A, Heidegger I.

Clin Genitourin Cancer. 2018 Oct;16(5):e1015-e1024. doi: 10.1016/j.clgc.2018.05.015. Epub 2018 Jun 8.

PMID:
29960831
8.

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators.

N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.

9.

Optimal time-point for 68Ga-PSMA-11 PET/CT imaging in assessment of prostate cancer: feasibility of sterile cold-kit tracer preparation?

Beheshti M, Paymani Z, Brilhante J, Geinitz H, Gehring D, Leopoldseder T, Wouters L, Pirich C, Loidl W, Langsteger W.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1188-1196. doi: 10.1007/s00259-018-3970-y. Epub 2018 Feb 23.

PMID:
29476228
10.

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ; SPARTAN Investigators.

N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8.

11.

Neoadjuvant Chemotherapy with Gemcitabine plus Cisplatin in Patients with Locally Advanced Bladder Cancer.

Niedersüss-Beke D, Puntus T, Kunit T, Grünberger B, Lamche M, Loidl W, Böhm R, Kraischits N, Kudlacek S, Schramek P, Meran JG.

Oncology. 2017;93(1):36-42. doi: 10.1159/000463389. Epub 2017 Apr 12.

PMID:
28399521
12.

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators.

N Engl J Med. 2017 Mar 16;376(11):1015-1026. doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17.

13.

Evaluation of Prostate Cancer Bone Metastases with 18F-NaF and 18F-Fluorocholine PET/CT.

Beheshti M, Rezaee A, Geinitz H, Loidl W, Pirich C, Langsteger W.

J Nucl Med. 2016 Oct;57(Suppl 3):55S-60S. Review.

14.

32nd International Austrian Winter Symposium : Zell am See, the Netherlands. 20-23 January 2016.

Langsteger W, Rezaee A, Loidl W, Geinitz HS, Fitz F, Steinmair M, Broinger G, Pallwien-Prettner L, Beheshti M, Imamovic L, Beheshti M, Rendl G, Hackl D, Tsybrovsky O, Steinmair M, Emmanuel K, Moinfar F, Pirich C, Langsteger W, Bytyqi A, Karanikas G, Mayerhöfer M, Koperek O, Niederle B, Hartenbach M, Beyer T, Herrmann K, Czernin J, Rausch I, Rust P, DiFranco MD, Lassen M, Stadlbauer A, Mayerhöfer ME, Hartenbach M, Hacker M, Beyer T, Binzel K, Magnussen R, Wei W, Knopp MU, Flanigan DC, Kaeding C, Knopp MV, Leisser A, Nejabat M, Hartenbach M, Kramer G, Krainer M, Hacker M, Haug A, Lehnert W, Schmidt K, Kimiaei S, Bronzel M, Kluge A, Wright CL, Binzel K, Zhang J, Wuthrick E, Maniawski P, Knopp MV, Blaickner M, Rados E, Huber A, Dulovits M, Kulkarni H, Wiessalla S, Schuchardt C, Baum RP, Knäusl B, Georg D, Bauer M, Wulkersdorfer B, Wadsak W, Philippe C, Haslacher H, Zeitlinger M, Langer O, Bauer M, Feldmann M, Karch R, Wadsak W, Zeitlinger M, Koepp MJ, Asselin MC, Pataraia E, Langer O, Zeilinger M, Philippe C, Dumanic M, Pichler F, Pilz J, Hacker M, Wadsak W, Mitterhauser M, Nics L, Steiner B, Hacker M, Mitterhauser M, Wadsak W, Traxl A, Wanek T, Kryeziu K, Mairinger S, Stanek J, Berger W, Kuntner C, Langer O, Mairinger S, Wanek T, Traxl A, Krohn M, Stanek J, Filip T, Sauberer M, Kuntner C, Pahnke J, Langer O, Svatunek D, Denk C, Wilkovitsch M, Wanek T, Filip T, Kuntner-Hannes C, Fröhlich J, Mikula H, Denk C, Svatunek D, Wanek T, Mairinger S, Stanek J, Filip T, Fröhlich J, Mikula H, Kuntner-Hannes C, Balber T, Singer J, Fazekas J, Rami-Mark C, Berroterán-Infante N, Jensen-Jarolim E, Wadsak W, Hacker M, Viernstein H, Mitterhauser M, Denk C, Svatunek D, Sohr B, Mikula H, Fröhlich J, Wanek T, Kuntner-Hannes C, Filip T, Pfaff S, Philippe C, Mitterhauser M, Hartenbach M, Hacker M, Wadsak W, Wanek T, Halilbasic E, Visentin M, Mairinger S, Stieger B, Kuntner C, Trauner M, Langer O, Lam P, Aistleitner M, Eichinger R, Artner C, Eidherr H, Vraka C, Haug A, Mitterhauser M, Nics L, Hartenbach M, Hacker M, Wadsak W, Kvaternik H, Müller R, Hausberger D, Zink C, Aigner RM, Cossío U, Asensio M, Montes A, Akhtar S, Te Welscher Y, van Nostrum R, Gómez-Vallejo V, Llop J, VandeVyver F, Barclay T, Lippens N, Troch M, Hehenwarter L, Egger B, Holzmannhofer J, Rodrigues-Radischat M, Pirich C, Pötsch N, Rausch I, Wilhelm D, Weber M, Furtner J, Karanikas G, Wöhrer A, Mitterhauser M, Hacker M, Traub-Weidinger T, Cassou-Mounat T, Balogova S, Nataf V, Calzada M, Huchet V, Kerrou K, Devaux JY, Mohty M, Garderet L, Talbot JN, Stanzel S, Pregartner G, Schwarz T, Bjelic-Radisic V, Liegl-Atzwanger B, Aigner R, Stanzel S, Quehenberger F, Aigner RM, Marković AK, Janković M, Jerković VM, Paskaš M, Pupić G, Džodić R, Popović D, Fornito MC, Familiari D, Koranda P, Polzerová H, Metelková I, Henzlová L, Formánek R, Buriánková E, Kamínek M, Thomson WH, Lewis C, Thomson WH, O'Brien J, James G, Notghi A, Huber H, Stelzmüller I, Wunn R, Mandl M, Fellner F, Lamprecht B, Gabriel M, Fornito MC, Leonardi G, Thomson WH, O'Brien J, James G, Hudzietzová J, Sabol J, Fülöp M.

EJNMMI Res. 2016 Apr;6(Suppl 1):32. doi: 10.1186/s13550-016-0168-9. Epub 2016 Apr 18.

15.

Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy.

Fajkovic H, Mathieu R, Lucca I, Hiess M, Hübner N, Al Hussein Al Awamlh B, Lee R, Briganti A, Karakiewicz P, Lotan Y, Roupret M, Rink M, Kluth L, Loidl W, Seitz C, Klatte T, Kramer G, Susani M, Shariat SF.

Urol Oncol. 2016 May;34(5):233.e1-6. doi: 10.1016/j.urolonc.2015.10.013. Epub 2016 Mar 10.

PMID:
26973136
16.

Austrian recommendations on Targeted Hormone Therapy for metastatic, castration-resistant prostate cancer.

Ponholzer A, Loidl W, Bektic J, Dorfinger K, Hruby S, Jeschke K, Kramer G, Krause S, Ludvik G, Remzi M, Roider M, Stoiber F.

Wien Klin Wochenschr. 2016 Feb;128(3-4):156-63. doi: 10.1007/s00508-015-0945-x. Epub 2016 Feb 1.

PMID:
26831188
17.

The prognostic role of preoperative serum C-reactive protein in predicting the biochemical recurrence in patients treated with radical prostatectomy.

Sevcenco S, Mathieu R, Baltzer P, Klatte T, Fajkovic H, Seitz C, Karakiewicz PI, Rouprêt M, Rink M, Kluth L, Trinh QD, Loidl W, Briganti A, Scherr DS, Shariat SF.

Prostate Cancer Prostatic Dis. 2016 Jun;19(2):163-7. doi: 10.1038/pcan.2015.60. Epub 2016 Jan 26.

PMID:
26810014
18.

Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1).

De Santis M, Wiechno PJ, Bellmunt J, Lucas C, Su WC, Albiges L, Lin CC, Senkus-Konefka E, Flechon A, Mourey L, Necchi A, Loidl WC, Retz MM, Vaissière N, Culine S.

Ann Oncol. 2016 Mar;27(3):449-54. doi: 10.1093/annonc/mdv609. Epub 2015 Dec 16.

19.

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ; METEOR Investigators.

N Engl J Med. 2015 Nov 5;373(19):1814-23. doi: 10.1056/NEJMoa1510016. Epub 2015 Sep 25.

20.

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P; CheckMate 025 Investigators.

N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25.

Supplemental Content

Loading ...
Support Center